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A bstract: D espite trem endous research efforts at every level, globally, there is still a lack of effective 
drugs for the treatm ent of A lzheim er's disease (AD). The biochem ical mechanism s of this devastating 
neurodegenerative disease are not yet clearly understood. This review  analyses the relevance of 
multiple ligands in drug discovery for AD as a versatile toolbox for a polypharm acological approach 
to AD. H erein, w e highlight m ajor targets associated w ith AD , ranging from  acetylcholine esterase 
(AChE), beta-site amyloid precursor protein cleaving enzym e 1 (BACE-1), glycogen synthase kinase
3 beta (GSK-3ß), N-m ethyl-D-aspartate (NMDA) receptor, m onoamine oxidases (MAOs), metal ions in 
the brain, 5-hydroxytryptam ine (5-HT) receptors, the third subtype of histamine receptor (H3 receptor), 
to phosphodiesterases (PD Es), along w ith a sum m ary of their respective relationship to the disease 
network. In addition, a m ultitarget strategy for AD is presented, based on reported m ilestones in this 
area and the recent progress that has been  achieved w ith  m ultitargeted-directed ligands (M TDLs). 
Finally, the latest publications referencing the enlarged panel of new biological targets for AD related 
to the m icroglia are highlighted. However, the question of how  to find m eaningful com binations of 
targets for an M TD Ls approach rem ains unansw ered.
K eyw ords: m ultitarget drug discovery; M TD Ls; tacrine; donepezil; A C hE inhibitors; BACE-1 
inhibitors; GSK-3ß inhibitors
1. Introduction
In  1906, A lois A lzheim er presented his first signature case and the pathological features of the 
disease w hich, from 1910, becam e known as A lzheim er's disease (AD). AD is clinically characterized 
by  a loss of m em ory, the retardation of th inking and reasoning, and changes in  personality  and 
behaviours [1,2]. N ow adays, approxim ately  40 m illion people over the age of 60 suffer from  AD  
w orldw ide, and the num ber of patients is increasing, w ith  the perspective of cases doubling every 
20 years [3]. A D  is a progressive and irreversible neurological disorder occurring in  the central 
nervous system  (CNS) m ainly confined w ithin the hippocam pus and the cerebral cortex, dom ains of 
the forebrain related to m em ory and higher cognitive functions. The histological m anifestation of 
A D  presents extracellular deposits o f ß-am yloid  peptide (A ß) and the intracellu lar form ation of 
neurofibrillary tangles consisting of paired helical filaments of hyperphosphorylated tau protein [4,5 ]. 
A D  is a com plex and m ultifactorial disease, w hich  m eans that it is influenced by  a com bination 
of m ultiple genes and environm ental/risk  factors. In  the early 1990s, m utations in the genes of 
am yloid-beta A 4 precursor protein (A PP), presenilin  1 (PSEN 1), and presenilin  2 (PSEN 2) w ere
Molecules 2020, 25,3337; doi:10.3390/molecules25153337 www.mdpi.com/journal/molecules
determ ined for fam ilial AID* [(5- 8 ] . Presenilins are com ponents of the y-secretase com plex w hich, 
w hen m utated, can affect am yloid  precursor protein (APP) processing to form  toxic form s of A ß. 
In apdition to genes, genetic risk loci for AD wpre deOermined and one of them, apolipoprotein E, type 
e4 allele (A PO E e4)° is associated w ith  late-onset fam ilial A D  S9,10]. Studios on the; b iad in g  of apoE 
(a peptide corresponding to the low -density  lipoprotein receptor binding dom ain) to APP, show ed 
that blocking of the interaction of apoE w ith  N -term inal A PP reduces A lzheim ar's-ossociated  A ß 
accum ulation and tou j^atloologies id the brain  [Id ]. K now n risk factors include age, having a  fam ily 
history of AD , A PO E r4, vascular problem s (heart disease, strokec high blood pressure), diabetes, 
and obesity  [ 12, l h]. Howevhr, the rensons w hy sporadic A D  occurs is ctill unknow n. There are 
variouo descriptive hypotheses regarding the causes o f rporad(c A D , including the cholinergic 
hypohhesis [13], am yloid  hypothesis [h4- l f ], tau  propagation hypotheeit [tS ,18], m itochondrial 
coscade hypothesis [he,04], catcium hom eostasis hypothesio [oo,2c ], inflam m atoiy hypothesis [23- 25], 
neurovaoc ular hypothe^o [26], mefal ion hopothesis [2e-3 9 ]a and lymphatic sysitr^rtt hypotheois [30,4 t ] . 
M oreover, there; are m any factors that m ay associated w ith  AD, such as various m icrobes (triggering 
am yloidosis), viral pathogens (Herpesviridae tam ily) [h i,55], decreased expression of m icroRN A s-107 
(m iRN A -107) [354:—758]̂ and R A S-R A F-M EK  signalling p athw aa ([«aUŜ ĉ ppiî  of neurons) [39], regional 
hypom etabolism  ^ 0,44], aneh m itochondrial dysfunction [4h- 4 2]. In summary, the aetiology of AD is 
recognized but not fully understood.
Currently, there ace a total of five therapies Sn the clinic, and foaa chugs approved by the FDA for 
A D  (Table e) , w hiW  m o stly aim  at restoring physiolog 'cal A C h levelc. The inhibition of tico enzym e 
ocetylcholinei-ilr^i'^s^ (AChE), responsible Pot the hydrolysis od Ach, io ths main biochem ical mechaniam 
of action of donepezil, rivastigm ine and galantam ind. In turn, m em antine, through noncom petitive 
antagonism  of She N -m ethyl-D-aspartate (INUDA} ^oce pr̂ ôr, blocks current flow, iespecial calcium) and 
red u cesth e excitotodic effeot of glutam ate [45].
Table 1. Drugs approved for AD therapy.










-AChE competitive and 
reversible inhibitor 
AChR subunit alpha-7 allosteric 
modulator 
-N AChR allosteric modulator 
-ChE inhibitor
-selectively and reversibly 
inhibits AChE 
-improves the cognitive and 
behavioral signs and symptoms 
of AD 
-neuroprotective
-parasympathomimetic and a 
reversible cholinesterase 
inhibitor 
-inhibits both BuChE and AChE 
-enhances cholinergic function
-enhances cholinergic function 
-improve cognitive performance 
in AD 
-not considered as a 
disease-modifying drug
Table 1. Cont.
Drug Structure Targets Therapeutic Effects
-NMDAR uncompetitive 
(open-channel) antagonist 
-Alpha-7 nicotinic cholinergic 
receptor subunit antagonist
memantine
-inhibits calcium influx into cells 
that is notmally caused by 
chronic NMDAR activation by 
glutamate 
-enhances neuronal synaptic 
plasticity
D rugs only provide tem porary sym ptom atic relief am ong patients w ith  m ild-to-m oderate 
sym ptom s of A D , bu t d o not provide a cure; or proteelion. Thus, one of the largest u nm et m ed ita l 
needs is a m odifying treatm ent for AD. The com plicated pathogenesis of AU, in association w ith the 
various descriptive hypotheses involved in the onset and developm ent of the disease and along w ith 
the im perfect single-target drugs available, foom an excellent rational basis for the im plem entation of 
m ulti-targeg strategies as part of the d rug discoveey pipelm e against tAD. bfie multi-narget-ditectdd 
ligands (M TD Ls) stratagy foresees the developm ent o f a single m idecule aMe to affect several key 
targetsepaphways, w hich can have a  synergistic effect on the A D  netw ork, leading to superior 
im provem ent on m em ory and cognition. W hile the idea of M D TLs is sim ple at a glance, the rational 
design of a com pound in w hich  twu or m ore pharm acophores are com bined in a single m olecular 
entity  is a challenge. H erein, w e highlight m ajor targets associaUed w ith  A D  and collate the latest 
publications w hich have resulted in an enlaaged panel of drug targets.
2. A D -R elated  Targets
Exploration of hypotheses regarding the caus es of A D  focus on m ajor pathogenesis factors and 
pathw ays (Figure r ) . F irsffy  cholinergic deficit, w hich led to the discovary of fha prim ary AD targets 
of acetylcholinesterare (AChE) and butyeylocholinosterase (BuGvE). N ext, for am yloid aggregation, 
w here the m ain target is beta-aecretase 1 (BA CE-1), w hereaa for the hyjrerjoliospliorylation of tau 
protein, glycogon synthase kinase 3 beta (G SK -3ß) and cyclin dependent ldnase 5 (Cdk5) are the key 
targets. Increared oxidative dam age and inflam m ation and unbalance-  ^ m e o s ta s is  of biometoLls in 
the couose of AD led to the; discovery of farther potential targets for AD treotment.
Figure 1. Multiple pathological pathways of AD.
M oreover, the pathogenesis of AD involves num erous receptors, namely, (N -m ethyl-D-aspartate 
(NMDA), 5-hydroxytryptam ine (5-HT) serotonin, the third subtype of histamine receptor (H3 receptor), 
and enzym es, nem ely  m onoam inoxidases (M A Os), and phosphodiesterases (PDEs). The first AChE 
inhibitor (A ChEI) for A D  treatm ent, tacrine, w as approved in  1993. H ow ever it w as w ithdraw n 
shortly after release due to livee toxicity  [46] (Figure 12). Currently, the inhibition of A C hE is a 
fu n dameneal jtroprrty of drugs approved by the FDA which are principally AChE inhibitors (AChEIs), 
such as donepezil, galantam ine, and rivastigm ine. Even so, tacrine and denepezil are still the 
targets for m odifications or are used as positive controls in enzym e or pharm acological activity tests. 
The cholinergic hypotheois, com bieing  A C h and A C hE as a com m on moolality is em erging as a 
prom ising approach in designing M TD Ls for AD . The first clinical exam ple of this approach w as 
caproctam me, w hich was reported m 1998 as a com poend with noncovalent inhibitory nctivity against 
the cholinergic system  and acetylcholinesterase [47].
Reversible ACOEI 
IC50 hACOE = 320 tM  
IC50 hBuCOE = 80 hM
pIC50 ACOEI = 6.77 pM 
pIC50 BuCOEI = 4.30 pM 
inhibition nf Aß aggregation < 5%
Figure 2. Tacrine and captopramine.
Later, the am yloid cascade hypothes is w as proposed to explore the m echanism  of A D  and has 
been the gold-standard-beta-am yloid dogma for alm ost 30 years [48] and has becom e one of the m ost 
dom inant research focuses conducted in academra arO the pharmareuOical industry.
The typical hallm arks of A D -synaptic dysfunction and senile plaques— are consequences of 
the production, oligom eri zotisn  and eelf-aggregatton of bOta-amyloid (A ß). A m yloid precursor 
proteiO (APP) is degraded via tire non-am yloidogenic (catalyzed bp a-secretase and y-seteetase) aOd 
am y lo id oten lc pathw ays, w here the; degragation  Oy ß-secretase (BA C E-1) and y-secretaso generate 
A ß species. The A ß species are com posed of 37-49  amino acid residuesr w ith the m ajor species being 
A ß40, w hereas the m ajor type from the m inor species is A ß42. A ß40 is the m ore com m on m etabolite 
and m ay actually  be anti-am yloidogenlc [49], w hareas A  ß42 and other longer peptides are highly 
self-aggregating and lead to profound A ß deposition [50,51]. Studies of A D -causing m utations in 
APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) ganes dem onstrate that the vast m ajority oO these 
m utations altee TAPP processing in a m anner that either incre ases the ab solute or relative levels of 
A ß42 [52i .
The key histopathological hellmarlc of AD is (he senile plaque-intracellular neurofibrillary tangles 
in the brain. Tangles are com posed of paired helical filam ents and straight filam ents w hich  are 
mainlO caused by  hyporphosphorylated tau protein [53j . The tau  protein hypothesis of A D  is 
based on hyp erphos phoryjation of the tau pro tein jfrom  the 2 -3  to thee 5 -9  phosphate groups) by the
threonine-serine kinase, GSK-3 ß . Such hyperphosphorylated tau protein is separated from microtubules 
and subsequently aggregates into insoluble intracellular neurofibrillary tangles w hich ultim ately cause 
cell death [54,55]. GSK-3 ß is a pivotal kinase in neurodevelopm ent and involved in both physiological 
and pathological aging. In the non-am yloidogenic pathway, GSK-3 ß m ay dow n-regulate the activity 
of the a-secretase complex through inhibition of metalloproteinase (ADAM) activity [56] and regulates 
A ß production by  interfering w ith  A PP cleavage at the y-secretase com plex [57]. In turn, in the 
am yloidogenic pathway, G SK -3ß inhibition reduces BA C E1-m ediated  cleavage of A PP through a 
nuclear factor kappa-light-chain-enhancer of an activated B cell (N F-k B) signaling-mediated mechanism. 
This observation thus suggests that the inhibition of GSK-3 ß reduces Aß pathology [58- 60] and GSK-3 ß 
plays a key role in  choline m etabolism , w hich  involves the regulation of choline acetyltransferase 
(ChAT) and AChE [61,62]. Further, GSK-3 ß has the capacity to phosphorylate several mitogen-activated 
protein kinases (M A PK s), thus regulating axonal stability. Inhibitors of G SK -3 ß provide protection 
from intrinsic apoptotic signaling, but potentiate that of extrinsic apoptosis [63].
G SK 3ß m ediates an  interaction betw een tw o m ajor form s of synaptic plasticity  in  the 
brain, N -m ethyl-D -aspartate (N M D A ) receptor-dependent long-term  potentiation (LTP) and N M D A  
receptor-dependent long-term  depression (LTD). LTP and LTD of hippocam pal synaptic transm ission 
represent the principal experim ental m odels underlying learning and memory. In m ouse m odels of 
AD, early im pairm ents in synaptic transm ission were caused, among other factors, by A ß, w hich leads 
to im pairm ent of LTP via tau protein [64] . In the norm al brain, activation of G SK 3ß is essential for 
N M D A  receptor-dependent LTD, and its activity can be regulated by LTP. Follow ing the induction 
of LTP, there is inhibition of G SK 3ß activity, w hereas G SK 3ß inhibitors b lock  the induction of LTD. 
In addition, GSK-3 ß has been identified as a prom inent regulator of inflammation via the promotion of 
the production of proinflam m atory cytokines (interleukin-6(IL-6), IL -1ß) and tum or necrosis factor 
(TNF), or by  decreasing the production of the anti-inflam m atory cytokine, IL-10 [65,66]. To conclude, 
G SK -3 ß inhibition is a popular target for sm all m olecule com pounds, m ainly  based  on the three 
therapeutic approaches, nam ely the inhibition of phosphorylation, prevention of the aggregation of 
tau protein, and stabilization of m icrotubules.
N M DA receptor plays a crucial role in m odifying major forms of synaptic plasticity, certain types 
of learning and m em ory form ation, as w ell as consolidation of short-term  m em ory into long-term  
m em ory under physiological conditions [67]. The glutam atergic (NM DA) hypothesis of AD  is based 
on the observation that inhibition of the N M D A  receptor w ould am eliorate the overall condition of 
A D  patients. However, N M DA cannot be fully antagonized since it exerts im portant bio-functions in 
normal synaptic transmission, whereas glutamate-related excitotoxicity and cell death could be caused 
w hen N M D A  receptors are overstim ulated by excess g lutam ate [68]. Thus, establishing an optim al 
balance betw een glutam ate stim ulation and glutam ate-related excitotoxicity is crucial to achieve the 
m ost effective treatm ent of AD.
O ther targets for AD are the m onoam ine oxidase (MAO) enzymes, a group of enzymes consisting 
of tw o d istinct isoform s (M A O -A  and M A O -B) w hich, by deam ination, lead to the m etabolism  of 
am ine neurotransm itters (e.g., m onoam ine neurotransm itters). In AD  patients, the activity and gene 
expression of M AO-A is up-regulated in different brain areas [69,70] as w ell as M AO-B [71]. High levels 
of M A O s catalyze oxidative deam ination, increasing the production of hydrogen peroxide and 
reactive oxygen species (ROS), which are responsible for oxidative injuries and the toxic environm ent 
characteristic of neurodegeneration [72,73] and increased M AO-B levels can enhance astrogliosis in the 
brain [74,75].
AD may be im plicated by high levels and dysregulation of Cu2+, Fe2+, Zn2+, and Ca2+, w hich are 
im portant biom etal ions [76,77]. C u 2+ and Z n2+ are know n to induce the generation of toxic 
A ß oligom ers by binding to A ß peptides and influencing the A ß aggregation pathw ay [78,79], 
the redox-active m etals, Cu(I/II) and Fe(II/III) generate cytotoxic reactive oxygen species (RO S) [80]. 
Thus, the use of biom etal chelators that can down-regulate high levels of biom etals could be a potential 
therapeutic strategy for the treatm ent of AD. The serotoninergic neurotransm itter and histam inergic
system s play a critical role in the regulation of the CN S. Brain  functions m ediated by 5 -H T 4R and 
5-H T fR  require a synergistic effect from  cholinergic neurotransm itsion. A ctivation of 5 -H T4R can 
enhance i f e  release of A C h in the hippocam pus, w hereas 5-H TgR blockade enhance cholinergic 
neurotransm issien [e t,h2]. Moreover, 5 -HT4R agonists could prom cte the nonam yloidogenic cleavage 
of APPi which releases a solutile sA P P a fragm ent w hich, in contrast tc  A ß , has pufative neurotrophic 
and neuroprotective properties [8i ] . TOe selective partial 5-H T 4 agoniet, RS-67333, w hich is a  potent 
cognttive and learning function enhancer, m ay reduce A ß production and has a neuroprotective 
activity  in  a cellular m odel of A D  [th- f ö ] . A ctivation of the htstam ine H 3 receptor decrease- the 
presynapiic release of A C h, and its bloakade augm ents the presynaptic telease of A ch, resulting in 
im proved cholineegic neuaotransm ission in the cortex. H ow ever, in clin ical trials, the H 3 receptor 
antagonists faifed to achieve cognitive im provem ent in AD  patients [87].
Im paired signaling pathw ays o f c y c l i c ^ '^ -  adenosine m onophosphate (cA M P) and 
cyclic-3',5 '-guanosine m onophosphate (cGMP) may contribute to the developm ent and progressi on of 
AD. Thus, phosphodiesterase inhibitors (PDEIs), such as rolipram androflum ilaat (PDE4Is)a vinpocetine 
(PDE1Ig cilostazol and miirinone (PDE3Is), sildenafil and tadalafil (PDE5Is) were found to be involved 
in the phosphorylation of tau, avgrehation of A ß , neuroinflamm ation as well as regulation of cagnition, 
m ood, and em otion processing;. D espite rational argum ents, the clinical data do not dem onstrate 
efiiaacy of selective PD EIs in  im proving cognition in patients w ith  prodrom al and m ild A D , and a 
num bcr ot these hcve been discontinued due to failure to m cet efficacy endpoints in a phase I/II clinical 
trial [88-9 0 ] . However, thee com bination therapy of donepezil w ith cilostazol show ed positive effects 
on patients with mild or m odcrate-to-severe A lzheim er's patients [c- ,92]. To conclude, there are many 
biological targets and signalling pathw ays involved in A D  pathology [93,94] . H ow ever, the com plex 
interactions betw een them is unclear.
3. M ulti-Target Strategy far AD
The complex nature of AD has led to the development of a m ultitarget approach in the design and 
development of new potential anti-AD drugs. At present, the M TDLs strategy can be divided into two 
m ain categories based on the biological targets, namely, involving AChE or distinct to AchE. The first 
category is m ainly based on  inhibitors of A C hE/BuC hE and ß-am yloid  aggregation. The success 
of m em oquin and ferulic acid-m em oquin hybrids (Figure 3 ), w hich can inhibit both  A C hE- and 
self-induced A ß aggregation, open exciting new  opportunities for M TD Ls drug discovery [95- 97].
ICco hAChEI = l.CC nM  
ICco BA C E-1I = 108 nM  
ICco A|342 rcif-aggrcgatiag  : 
C.93 pM
ICco AC hEI = 3.2 nM  
BhA C hEI (%) = 36. 2 
A|342 rcif-aggrcgatiag  
inhibition = 26.8 pM  (10 pM)
Figure 3. Memoquin and 17d, the most active ferulic acid-memoquin hybrid, from [97].
The M TD Ls involving A ChE consist m ainly of tacrine- or donepezil-related com pounds. 
Tacrine and donepezil are non-com petitive and reversible C hE inhibitors and alleviate neuronal 
degeneration caused by  dam age of cholinergic transm ission. O n the other hand, A C hE has becom e
to be regarded as an inducer to trigger the aggregation of A ß . Interaction of a peripheral anionic 
site of A C hE w ith  A ß could facilitate fibril form ation. B locking the peripheral anionic site of A ChE 
has been  identified as an effective m ethod for inhibition of A ß aggregation [98]. The sim ultaneous 
binding to a catalytic active and a peripheral anionic side of AChE (dual-site inhibitors) is an example 
of successful adaptation of an M TD Ls design strategy applied in the m ost prevalent and dom inant 
class of tacrine hybrids. However, various donepezil-based cholinesterase inhibitors could also show 
additional inhibition of A ß aggregation, oxidative stress, and M A O s. M TD Ls based  on tacrine and 
donepezil scaffolds are described in Table 2 .
Table 2. Examples of MTDLs based on tacrine and donepezil scaffolds.
Scaffold Lead Fragment Targets Ref.
xanomeline, iperoxo-fragment AChE Is and MRs [99]
valmerin AChE Is and GSK-3a/ßIs [100]
deferasirox AChE Is and metal chelators [101]
indole-3acetic acid AChE/BuChE Is [102]
pulmonarin B AChE/BuChE Is [103]
Tacrine D-xylose, D -ribose, D -galactose AChE/BuChE Is [104]
acridine AChE/BuChE Is [105]
1,2,3-thiadiazole AChE/BuChE Is [106]
ferulic acid AChE/BuChE Is [107]
flavonoid quercetin AChE/BuChE Is and metal chelators [108]
quinolone carboxylic acids AChE/BuChE Is, M1R Is [109]
hydroxyphenyl-benzimidazole AChE Is and metal chelators [110]
hydroxybenzimidazole AChE Is and metal chelators [111]
butylated hydroxytoluene hybrids AChE Is, MAO-B Is, antioxidants [112]
trolox AChE Is, MAO-B Is, metal chelators [113]
Donepezil chromone AChE Is, MAO-B Is [114,115]
chalcones AChE/BuChE Is [116]
2-acetylphenol AChE/BuChE Is, MAO-A/B Is, metal chelators [117]
deoxyvasicinone AChE Is and BACE-1 Is [118]
introduction of amide bonds AChE Is and BACE-1 Is [119]
conjugation of benzylpiperidine AChE Is, antioxidant, [120]moiety benzimidazole or metal chelatorsbenzofuran
melatonin AChE/BuChE Is, antioxydants, metal chelators [121]
3.1. AChE and BACE-1 Inhibitors
The analysis of the SciFinder database show ed that there w ere alm ost 567 articles (original and 
review) related to com bining the functionality of AChE drugs and BACE-1 inhibitor pharm acophores 
over the last decade. M TD Ls w hich  contain  a pharm acophoric m oiety derived from  tacrine are 
potent BA C E-1 inhibitors, inhibitors of tau-protein aggregation and possess additional properties 
(antioxidative, neuroprotective or metal chelating ability) [122- 127] as w ell as another major chemical 
group consisting of donepezil-related compounds [121,128- 136]. Moreover, miscellaneous compounds 
based on the cyanopyridine, quinazoline, quinoline, benzo-chrom ene, pyrim idinim ine, and thiazole 
cores are inhibitors of both AChE and ß-amyloid aggregation and some of them  possess antioxidative 
properties and inhibitory potency against BACE-1 [137].
A  fam ily  of tacrine and 4-oxo-4H -chrom ene hybrids w as reported by  Fernandez-Bachiller and 
co-w orkers. The m ost prom ising com pound (Figure 4 ) exhibited potent inhibition activity against 
hum an AChE and BACE-1, antioxidant activity (1.3-fold more potent than a vitam in E analogue-trolox) 
and good CN S perm eability [138].
IC50 HAChEI = 8.0 nM  
IC50 BACE-1 = 2.8 pM
Figure 4. The most active tacrine and 4-oxo-4H-chromene hybrid from [138].
M unoz-Torrero et al. synthesized a series of heptam ethylene-linked levetiracetam -huprine and 
levetiracetam -6-chloro-tacrine hybrids w ith  potent inhibitory activities a  gainst hum an A ChE and 
BACE-1 and A ß42 anti-aggregating activity. The m os t m tererting com pound, (10, t ig a r e  5 ), redu ced 
the feequency of spontaneous convulsions, prevented mem ory im naiam eet and reduced the A ß burdan 
in the cortex of APP/PS1 m ice [ l t 5 ]. The presented hybrid protects ti/m sgeofe m ise from  cognitive 
deficits and, thereby, can be considered a m ultifunctional disease-m odifying nnti-A lzheim er agent. 
Additionally, tire g roup h a s ceporte d o n  second^eneration  anti-AD rhein-huprme hybrids w ith potent 
mhibiSory activities against hum an A ChE and BA C E-1 and A ß42 anti-aggregating activity  [139]. 
The m ost potent com pound (7e, Figure; 5), after intrnperitoneal ndmmistration in APP-PS1 transgenic 
m ice, shew ed a central effect in low ering nolu ila A ß [1/ 0].
D ata fnr comp. (10)
ICso hACCE I = 4 .r  nM  
ICso BACE-1 = 232 nM
Aß42 inCibitinn of self-aggregation = 36.4 % 
(20 pM)
D ata fnr comp. (7e)
ICso hACCE I = 3.0 nM  
ICso BACE-1 = 80 nM/
Aß42 inhibition of self-aggregation = 47 % 
(10 pM)
Figure 5. The most active levetiracetam-huprine and rhein-huprine hybrids from [125,140].
Zha et al. designed and synthesized novel tacrine-ben zofu ran  derivatives containing am ino 
or am ido linkages. M ost hybrids exhibited good inhibitory activities on A C hEs and ß-am yloid  
self-aggregation. The m ost prom ising com pound (2e, Figure 6 ) show ed an  interesting profile as 
a subnanom olar selective inhibitor of hA ChE and a good inhibitor of both  ß-am yloid aggregation 
(hA ChE- and self-induced, 61.3%  and 58.4% , respectively) and hBACE-1 activity. This hybrid  also 
exhibited low er hepatotoxicity  than tacrine and in vivo studies confirm ed its ability to penetrate 
the BBB. N ext, in  scopolam ine-induced m em ory im pairm ent studies in knock-out m ice, the hybrid 
significantly am eliorated m em ory perform ance of m ice in a M orris w ater m aze test [126].
Data for comp. (2e)
IC50 hAChEI = 0.86 nM
IC50 MACE-1 = 1.35 nM
A|342 inhibition of self-aggregation = 61 %
(10 pM)
F ig u re  6. The most active tacrine-benzofuran hybrid from [126].
3.2. AChE and GSK-3ß Inhibitors
Two im portant AD-related targets influencing; both ACh concentration modulati on and tau protein 
phosphorylation, are A C hE and G hK -3n. M TD Ls possessing; inhibitory nhtency for both  enoym es 
have been  rarely  renorted set far. Potent A C hE ćind G SK -3 ß d u aH arg et inM bitors w ere obtai ned 
by hyJnridioing the phorm rcophores o5 G SK -3 01 w ith  tVCTsIil. Thus, nachne w as incorporated aO the 
flniazolyl ring2 of potent G SK -3ßI w ith  an appropriate linker. Tire most: prom ising hybrid fhow ed 
o h  m ost intereyting profile as a nanom olar dual anoym e inhibitor, good inhibffory effert on A 3 
seff-aggregation, inhibition of tau  protem  hyperphosphorylation, and significant in vivo crnggni.tiâ ł̂e 
im provem ent in m ice tests [14 . ] . H ui e2 al. hnked tacrine (A ChEI) w ith  phenotilriazine v.iić3L an 
alkylenediam m p-type spacer. Phenothiazine in a core of m ephylthiom nium  chloride, allso lnnown ns 
mathylene Hue or Rember®, w hicn tras bocjecri shown to reduce tcu êevet̂ ls trr vitro and in vivo in several 
ditferent m echanism s of tction  f l !̂t ,2.o3]. In addition, ćrrf appropriyte linker som aining i2 a^^ -triazo le  
m oiety for two scaffolds, tacrine and valm erin (GSK-3<x 5I1), was designed bosed on m olacular docking 
and crystallography 1 00 ] (Figure 7).
D ata lo t to p p . (R ) - 6  
IC 50 hAChni = 9.5 nM  
IC 50 G SK -3a/ß l = 7 n M
F ig u re  7. Tacrine and valmerin hybrids from [100].
3.3. AChE and MAO Inhibitors,
M TD Ls strategies involving the A ChE and M A O s targets im the SciFinder data base show ed 
over 400 articles (original and review ) related to com bining the functionality  of A ChE drugs and 
M AOIs [144- 151]. Ladostigil (Figure 8) was designed on the basis o° the structures of livastigm ine and 
rasagiline. H ow ever, clinical trials revealed that the drug0 faiied in ias pnimary endpoint of curbing 
progression from  m ild  cognitive im pairm ent to A D  [152,153] . H om o isoflavonoid M annich-based 
derivatives, the selective duat inhibitors of A C hE and M A O -B, exhibitsd  A o i1 -4 2 ) aggregation 
inhibitory eflocacy w ith ćtntio xidant prtivity end b iom etsl chelating abi lity [154] °
rC5o AChEI = 32 pm ol/L 
IC50 BuChEI = 0.48 pm ol/L 
IC50 M A O -A I = 300 pm ol/L
F ig u re  8. Ladostigil.
3.4. AChE Inhibitors and NMDA Antagonists
The degenerative process of cholinergic neurons in A D  are im plicated by excessive activation 
of the N M D A  receptor. Thus, N M D A  receptor antagonists can confront neurodegeneration and
AChEIs can recover m em ory and cognition. Nam zaric was approved in 20115 for the treatm ent of AD, 
using e once; -daily fixed-dost drug com bination comprised of m emantine hydrochloride and donepez il 
hydrochloride. The first rationally-designod m u ltifunctioaal ligand, carbacrine, w as obtained by 
integrating synergistic fraam ents of the chloro-substitutod tetzahydraacripine m oiety of 6-chlorotacrine 
and carbachol as the starting lead com ponents [155]. Carbacrine showed dual inhibitory activity against 
A C hE and the N M D A  receptor, blocking in vitro A ß self-aggregation and aggregation m ediated by 
A ChE, antagonizes N M D A receptors, and reduces oxidative stress [156] (Figure 9 ).
IC50 A C nEI = 2.15 p M  
ICso N M D A N R1/N R2A  100 m V = 0.74 pM 
Aß42 inhibition of self-aggregatiop = 36% 
(10 pM)
IC50 ROS inhibition = 23 pM
Figure 9. Carbacrine.
M ore recently, a new class of m ulti-target com pounds that com bine the structures of galantamine 
and mem antine have been designed. The most potent drug candidate, memagal (Figure 10), showed a 
rem arkable inhibitory potency against A ChE and N M D A  receptor inhibition w hich w as tested by  a 
[3H] M K-801 binding assay.
Ki N M D A [3M K-801] = 4.60 pM 
IC50 rat AChEI = 1.16 nM
Figure 10. Memagal.
O ptim ization of the dimebion structure (a multi-target antihistamine drug) led to compounds with 
a m ulti-target profile against both the A ChE and N M D A  receptors and self-induced A ß aggregation 
inhibitory potency [157], M akhaeva and co-workers fused dim ebon w ith phenothiazine, and obtained 
com p ounds w ith dual BChE and N M DA receptor-inhibit i on potency [158].
3.5. AChE Inhibitors and 5-HTR
M odulating neurotransm ission of A C h and 5-H T could be achieved through 5 -H T 4 and 5-HT6 
receptors (5-H TR). A ctivation of 5-H T4R  can enhance the release of A C h in the hippocam pus, 
5 -H T4R  agonists can prom ote the nonam yloidogenic cleavage of APP, form ing neurotrophic hum an 
soluble am yloid precursor protein a  (sA P P -a) fragm ents and decrease A ß secretion in  prim ary 
neurons [81]. M oreover, 5-H T6R antagonists are thought to have the ability  to enhance cholinergic 
neurotransm ission [82,159,160]. R S67333, a partial 5 -H T 4R  agonist w ell-know n for its precognitive 
effect, show ed a synergistic effect w ith  donepezil and low ered A ß levels by  directly inhibiting the 
activity of AChE [161]. In addition, the key pharm acophores of RS67333 and donepezil w ere merged 
into a single novel chem ical entity, leading to the d iscovery of donecopride [86], a dual-action 
AChEI and 5 -H T4 receptor agonist. D onecopride (Figure 11) stim ulates the nonam yloidogenic 5 -H T4
receptor-m ediated cleavage of A PP and has a greater potency in  prom oting neurotrophic sA PP-a 
release com pared w ith RS67333.
5 -H T4R partial agonist 
Ki h5-HT4 = 8.5 nM  
IC 50 hAChEI = 16 nM
Figure 11. Donecopride.
3.6. AChE Inhibitors and H 3R
The H 3 histam ine receptors (H 3R) regulate the release of histam ine, acetylcholine and other 
monoamines. Activation o f f !  3R decreases the presynaptic release of ACh, and its blockade augments the 
presynaptic rel ease of ACh and improves cholinergic neur otransmission in the cortex. Evaluatio n of H3R 
antagonists or inverse agonists revealed their promnesic properties and ability to modulate learnigg by 
improving m em ory consolidation [162]. One of these antagonistc or invgrse agonists o) H 3 R, pitolisant, 
has been  approved for clinical use in patients w ith  narpolepty [163,164]. Thus, synergistic effects 
on up-regulating synaptic levels of A C h could be achieved by involving A ChE and H 3R. Bajda et al. 
appfied docking-based virtual screening Coe novel m ultifupctional com pounds in a non-im idazole 
histam ine H 3R ligand library. The m ost prom ising derivatives com bined the flavone m oiety  via a 
six-carbon atom linker w ith a heteaocyclic moiety, such as azepanet pipeeidine or 3-m ethylpiperidine 
(Figure; 12). C om pound 17 show ed s t f  h ighest inhibitory activities tow ard cholinesterases as w ell as 
w ell-balanced potencies against H 3R  and both ChE enzym es [165]. H uang and co-w orkers reported 
a series of com pounds w ith  a quinoxaline scaffold that show ed related inhibitory activities against 
A ChE, H 3R, and BACE-1 targets [166] (Figure 12).
D ata for comp. (17)
Ki 5 -H 3R = 228 nM  
IC 50 hAChEI = 0.36 pM
IC 50 5 -H 3R antagonism  = 280 nM  
IC 50 5 -H 3R inverse agonism  = 189 nM  
IC 50 AC hEI = 483 nM  
BACE-1 46.6%  inhibition at 20 pM
Figure 12. Hybrid involving AChE and H3R from [165,166].
3.7. AChE Inhibitors and Biometal Chelators
Starting w ith the hypothesis that biom etal chelators that can down-regulate high levels of biometals 
could form a potential therapeutic strategy for the treatm ent of AD, Fernandez-Bachiller and co-workers 
reported a hybrid hieed w ith tacsine and the m etal chelator drug, clioquinol (Figure 13) [167].
IC50 AChEI = 5.5 nM  
Cu2+ m etal chelator
Figure 13. Hybrid of tacrine-clioquinol.
In turn, hybrids of tacrine and a flavone, nam ely coum arin, chromone or donepezil, and curcumin, 
exhibited a significant ability to inhibit AChE. Additionally, hybrids of tacrine and a flavone, such as 
coum arin, chrom one or donepezil and curcumin, exhibited significant ß-am yloid-reducing and metal 
(Cum  and Fe2+) chelating; properties [168o170] (Figure 14).
IC 50 AChEI = 0.13 pM 
Cu2+ and Fe2+ m etal chelator
IC 50 AC hEI = 592 nM  
Cu2+ and Fe2+ m etal chelator
IC 50 AChEI = 0.187 pM 
Cu2+ and Fe2+ m etal chelator
Figure 14. Hybrids of tacrine-flavone and donepezil-curcumin from [168-170].
W ichur et al. designed and synthesized novel l-benzylpyrrolid ine-3-am ine-based  BuC hE and 
BA C E-1 inhibitors w ith  activities tow ards A ß and tau protein aggregation, as w ell as concom itant 
antioxidant and m etal-chelating properties [171] (Figure 15).
Comp. 25b
IC 50 eq BuC hEI = S.94 pM 
Cu2+ m etal chelator 
A ntioxidant properties
Figure 15. Inhibitor of BuChE with antioxidant and metal-chelating properties from [172].
3.8. BACE-1 and GSK-3ß Inhibitors
Even though the im portance of AChE in the AD signalling network is prominent, M TDLs strategies 
are also under consideration in the treatm ent of specific and m ultiple protein pockets of AD-associated 
targets. A nti-am yloid  based strategies n o t only focus on A ß alone, bu t also on effective m odulation 
of the robust netw ork of A ß-m ed iated  events. Thus, dual inhibitors of BA C E-1 and G SK -3ß show  
promise as drug candidates based on the inhibition of Aß and tau protein aggregation [172] (Figure 16).
Comp. E18
IC 50 A ß aggregation = 1.8 pM 
ICso tau aggregation = 1.4 pM
h
Figure 16. Oligo heteroaromatic hybrid with BACE-1 and GSK-3ß inhibitory activity from [172].
Table 1. G SK -3ß dual inhibitors w as obtainEd baded o n a  3 ,4-d ihydro-l,3 ,5-triazin-2(1H )-one 
skeleton. Subsequently, triazinones (6-am ino-4-phenyl-3,4-dihydro-1 and 3,5-triazin-2(1H )-ones), 
w ith  a  critical pharm acophore com prising the cyclic am ide group and guanidino m otif, have b te n  
shown to constitute a prom ising class of m ultifunctional fragments abte to m odulate tau and amyloid 
cascad et sim ultaneously (Figure 17) [173]. Bottegoni et al. reported an optim ized virtual screening 
m ethod to identify  fragm ents w ith  m ultifunctional activities against BA C E-1 and G SK -3ß [ 173], 
Anothee approoch described a series op dual inhibitors targeting BA C E-1 and G SK -3ß , based on 
curcum in derivatives [ 173] (F igu aet 7).
Comp. 2 from  [135] 
IC 50 B A C E ri =7 76 pM 
IC 50 GSK-ß ß = 3 pM
Comp. 2 from  [733] 
IC 50 B A C Eri =7 0.93 pM 
IC 50 GSK-ß ß = 0.90 pM
Figure 17. BACE-1 and GSK-3ß inhibitors.
3.9. Other Targets
The approved antifungal drug;, cliocu inol, w ith  an  8-hydroxyquinoline scaffold, w as show n 
to extract m etal ions from  extracellular A ß aggregates. Thus, a series of novel hybrids fused 
w ith  the m ain pharm acophoreu of selejpline and clioquinol, ihow ed  M A O -B inhibitory  pooency, 
antioxid  ant aftivity, b iom eta1 chelating ability, and effective inhibition against C u(II )-induced Ah 
aggregation [176].Clioquinol was then fused w ith the PDE9A inhibitor, PF-04447943, and the resulting 
hybrid  show ed inhibitory gotency  againsa PD E9 w ith  high selectivity  over other PD Es, notable 
Cu2+-induced A f  aggregation inhibition, and iavorabla b lo o d -lra in  barrier (BBB) perm eability [177]. 
N ew  persnoctives w ere preswnted by  novA  hybrids endow ed w ith  anti-inflam m atory and 
antkhollnbsterote activity  via trip le-iargeting  properties. H ybrids obtained through the m erger
of triazoles and th iosem icarbazides sim ultaneously  im pact on  cholinesterases, cydooxygenase-2 
(COX-2) and 15-lipoxygenase (15-LOX), and have em erged as prom ising new  hits [178].
Epigenetics involves the study of heritable and reversible changes in gene expression that cannot 
be explained by changes in the sequence of bases in genomic DNA but through covalent mod ifications 
to the cytosine residues of D NT A, covalent chemical m odifications in histones and chrom aiin remodeling, 
and noncoding RNAs. Such transcriptional dysregulation plays an im portant role in the progression 
and developm ent of AD m ainly through transcription of im m ediate early genes (IEGs), im portant for 
neuronal p lasticity, m em ory and behavior [179, ia 0 ]. Thus, there are interesting targets concerning 
epigenetics, especially lysine (K)-spocifk dem ethylase 1A (KDM 1A or LSD1) and histone deacetylase 
(HDAC). KDM 1A is a flavin adenine dinucleotide? IFAD) dependent amlne oxidase that acts primarily 
as a histone demethylase and has been im plicated in the control of IEG transcription. HDAC is involved 
in the daacetylati on of histone proteens w h ic f  prom ote heterochrom atin, leading to s ilenced gene 
transcription a n f  expresgion. KDM 1A and HDAC inhibitors have a promising therapeutic potential in 
recovering mem ory defects and cognitive disabilities through eliminating these diverse m olecular and 
cellular functions of HDAC enzym es in the brain .
Vafidem atat (ORY-2001i (Figure 18), an oral, brain  penetrating, d aa l K D M 1A /M A O -B inhibitor 
active at doses suitable for long-term  treatm ent, corrects m em ory gefocit in the Senescence Accelerated 
M ouse Prone 8 (S iM P 8 ) model for acceleraied tg ing and A lzheim er'c disease. Moeeover, m ultiple genes 
m odulated by O RY-2001 aro differentially expressud in late onset A lzheim er's disease. Vafidem stat is 
currently in m ultiple Phase IIa studies [181].
IG o K D M 1A = 101 nM  
IG o M AO -B = 73 nM
Figure 18. Vafidemstat (ORY-2001).
C uadaado-Tejedar et al. reporied  C M -414, a first-in  claso sm all-m olecule th ai acts as a dual 
inhibitor of H D AC and PDE5 (Figure C9). Inhibition of PDE5 induaes an increase in  the activation of 
cAMP/cGM P- responsive element-binding protein ( CREB) which combined witd mo dtrate HDAC c lass 
I inhib iti on, lead- ho efficient hisione acetylation. CM -414 rescued the im paired long-term  poteniiation 
evident in h ippocam pal slices from  A PP/PS 1 m ice, d im inished brain  A ß and tau phosphorylation 
(pTau) levels in chronic treatm ent of Tg2576 m ice [h82].
ICso HDAC1 = 310 nM  
IC50 H D A C2 = 490 nM  
ICso H D A C3 = 333 nM  
ICso H D A C6 = 91 nM  
ICso PDE5 = 60 nM
Figure 19. CM-414—first-in class dual inhibitor of HDAC and PDE5.
The com bined treatm ent of G SK -3 ß and H D A C  inhibition induces synergistic neuroprotective 
effects in various in vitro and in vivo m odels of neurological d iseases. D e Sim one et al. d iscovered 
the first-in-class G SK -3ß/H D A C  dual inhibitor as d isease-m odifying agent for A D  (Figure 20 ). 
C om pound 11 inducee an increase in histone acetylation and a reduction o l tau  phosphorylation. 
Moreoveo, St prom ofes neurogenesis and displays im m unom odulatory  effects. ft ic nontoxic and 
prolecthre against H 2 O 2  and 6-OH DA otimuli in SH -SY5Y and in C GN  ceil lines, respactively [183].
IC 50 HDAC1 = 12.78 pM 
IC 50 H D A C 6 = 3.19 pM 
IC 50 GSK-3 ß = 2.69 pM
Figure 20. GSK-3ß/HDAC dual inhibitor [184].
Transglutam inase 2 (TG2) is the m ost studied and expressed isoform  of the TG  fam ily  w hich 
is im portant in cross-linking proteins in A lzh eim er's disease. N ext, the genetic elim ination of 
TG2 in  H u ntington 's disease (H D) m ice m odels am eliorated the sym ptom s and restored the 
m essage and protein levels of brain-derived neurotrophic factor (BD N F). M oreover, the inhibition 
or genetic suppression of TG 2 halts oxidative stress-induced cell loss in cortical neurons [184,185]. 
Thus, neuroprotective effects c an be achieved by the TG2 and HDAC inhibiti on, which synergistic ally 
protects a gainst toxic stimuli mediated by glutamate. The m ost active compound (3) [(E)-N-hydroxy-5- 
(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanam ide] inhibit TG2 and HDACs 
both in -vitro and in cell-based assays (Figure 21 ). Furtherm ore, this nontoxic com pound protects 
cortical neurons against toxic insults induced by glutam ate [185].
In summary, a m ultitarget strategy for AD is em erging, involving a broad spectrum  of potential 
therapeutic strategies from  m odulating neurotransm ission, tau-based therapies, am yloid based 
therapies, m odulating intracellular signalling cascades, oxidative stress reduction, m odulation of 
cellular calcium  hom eostasis, to anti-inflam m atory therapy. R esearch in  the field of appltcation of 
M TD Ls strategy in the field of AD has been extensively reviewed elsew here [118,186- 188].
4. Physicochem ical Properties o f M T D L s for AID
M TD Ls are designed by com bining tw o (or m ore) pharm acophoric structural scaffolds, 
thus physicochem ical properties such as m olecular w eight, solubility, perm eability and the ability of 
M TD Ls to perm eate cell m em branes have to optim ized for absorption and distribution w ithin  tde 
body [189]. The “M p incki rule o( five ' (RO 5) [190] defined the optim al physicochem icar properties 
tor perorally  adm inistered drugs, w hich  are preferred for perspective long-term  treatm ent oC AD  
patients. RO5 postulated desirable physicochem ical property space ley setting up limits for1 m olecular 
w eight <  500D a, logarithm  of partition coefficient (logP; a value classifying the lipophilicity  of a 
compound) <  5, num ber of hydrogen bond donors (H BD s)< 5, and num ber of hydrogen bond acceptors 
(H BA d)< 10( A lthough R O 5 indicates possibiltty of absorption of drug afUer oral adm inistration, 
the rule is not specific for CN S drugs. It turns out that AD drugs need to fulfil strict physicochem ical 
cditeria defined for b leod -brain  barrier (BBB) penetration by transcelluiar passive diffucion, w hich is 
typical for m ost CNS drugs. Blood-to-brain influx i- m ediated by (he receptur for advanced glyca-ion 
end products (RAGE). Tire BBB efflux pum ps are transmembrane P-glycoprotein (P-gp), w hich m ediDe 
brain-to-blood transport. C ordon-Cdrdo et al. first suggested that P-gp m ighi play a role in viyo in 
lim iting brain penetration o i xenobiotics [191]. The high expression of P-gp is one of fhe m ain reasons 
ihai u lot o i lipophilic druus could n et penetrate CN S for brain disease therapy
Ex-ensive studies on physicochem ical propertips for C N S drugs laid out that m olecular w eight 
rhould not exceed 430 -4 5 0  D a, log;)3 values should be <  4 and the num ber uf H BD  and H BA  m ust
ICso HDAC1 =  3.38 pM 
ICso H D A C6 =  4.10 pM 
ICso TG2 =  13.3 pM
O
Figure 21. Dual TG2 and HDAC inhibitor from [185].
be <  2 and <  7, respectively  [192]. N ext, characterisation has been  com pleted w ith  topological 
polar surface area (TPSA ), Log D  and acid  d issociation constant (pK a). TPSA  counts the surface 
sum  over all polar atom s in  m olecule, and for m ost C N S drugs to be <  70 A 2 . LogD  is a pH 
dependent lipophilicity  ind icator d isp laying the distribution of a chem ical com pound betw een the 
lipid and aqueous phase. For CN S drugs logD is expected to be <3 . The strength of acidic functional 
groups in the m olecule expressed by pK a values for C N S drugs should be 7 -9 . For stream lining 
the design of proper physicochem ical properties of M TD Ls for AD , several pow erful predicting 
techniques, such as BBB-score and the C N S m ultiparam eter optim ization approach, have been 
developed. However, the m ost of M TDLs have been tested in a parallel artificial m embrane permeation 
assay (PAMPA), w hich  experim entally  determ ine perm eability  values w hich  w ould enable them  to 
cross the BBB by passive diffusion [125,127,132,193,194]. The current chem ical m ethods for crossing 
the BBB could be divided into chemical modification of the drug to form a prodrug, coupling the drugs 
w ith  m annitol or arom atic substances or u sing appropriate chem ical drug delivery system  or drug 
carrier w ith the ability to cross BBB [195].
5. Perspectives for M T D Ls in  the Treatm ent o f AD
A t present, only sym ptom atic treatm ents exist for AD , nam ely 3 cholinesterase inhibitors and 
m em antine, w hich  m ainly b lock  the progression of the d isease and are supposed to interfere w ith  
the pathogenic steps responsible for the clinical sym ptom s. A D  is a com plex disease, thus the 
rational way for searching for pathway-target-drug-disease relationships seemed to be a genome-based 
analysis [196,197]. K w ok et al. [198] used a gene-based test for the genetic validation  of potential 
A D  drugs, to provide an initial screening tool for the identification of drugs that are unlikely  to be 
successful. This study, however, provides no evidence that any approved or investigational AD drugs 
target products of genes strongly associated w ith  late-onset A D , w hich  m ight explain the lack  of 
efficacy to date.
M TD Ls tow ard A D  have to confirm  their sim ultaneous m ultitarget engagem ent in both in vitro 
and in vivo assay system s. Thus, the use of cellular m odels (cell-screening system s) of AD , based on 
hum an induced pluripotent stem  cell (hiPSCs) technologies could change preclinical research [199]. 
In  addition, the anim al m odels currently  available cannot fully reflect the m ultifactorial nature of 
hum an AD for m ultiple ligand testing. A ge-dependent neurodegeneration m ouse m odels that mimic 
A D  rely m ostly  on the neuronal overexpression of hum an proteins carrying a fam ilial A D -causing 
m utation in presenilin , w hich increases A ß 42 production and oligom erization [200,201]. In fact, 
w ith  respect to neurodegenerative diseases generally, m ouse m utations corresponding to hum an 
disease-linked m utations rarely  result in neurodegenerative phenotypes, m ostly  because age is the 
single greatest risk factor for neurodegeneration, and m ice have m uch shorter lifespans than hum ans.
Up to 2019, over 2000 clinical trials in AD drug developm ent had been reported in which various 
hypotheses for AD were tested. Liu et al. [25] reported that the amyloid hypothesis w as the m ost heavily 
tested (22.3%  of trials), w ith the neurotransm itter hypothesis being the second m ost tested (19.0%  of 
trials). In  turn, a system atic review  of the AD  drug developm ent pipeline in 2019, show ed that there 
were 132 agents in clinical trials and 90 agents in trials targeting cognitive enhancem ent, and a further 
14 trials intended to treat neuropsychiatric and behavioural aspects of AD [202]. Results suggested that 
there is a conceptual suprem acy for disease-m odifying therapies, as opposed to sym ptom atic-disease 
approaches [48]. From  96 agents reported in d isease m odification trials, 40%  have am yloid as the 
primary target, or as one of several effects, whereas seven small molecules and 10 biologics have tau as 
a prim ary or combination, target (18%). Until recently, AD drug development has been largely focused 
on beta am yloid plaques and tau tangles in  the brain. These attem pts have yielded less successful 
results than had been anticipated. Currently, some of the most novel non-amyloid approaches w ere put 
to the discovery and development of drugs for A lzheim er's and related dementias. Firstly, repurposing 
an existing drug accelerates the drug developm ent timeline. An example of this is the repurposing of a 
Parkinson's drug, rasagiline, that holds promise for slow ing the progression of A lzheim er's disease in
patients w ith  m ild cognitive im pairm ent [203]. In addition, new  drug candidates could restore lost 
cognitive function and lead to neuroprotective therapies for AD  and other forms of dem entia [204].
The diversification of targets and the entry of combination therapies into the potential therapeutic 
pipeline is particularly noticeable between phase 3  and 2 of clinical trials. The using of new biomarkers 
allow  early  assessm ents of the im pact of candidate interventions on disease b iology [202], how ever 
there is lack of accurate biom arkers to identify  and track  the progression of A D , w hich  has slow ed 
therapeutic developm ent in tauopathies.
So far, a w ide range of new  biological targets are under consideration as m icroglial targets 
(Table 3 ). M icroglia are a class of innate im m une cells (m acrophages) w ithin  the CN S. M icroglia 
fulfil a num ber of varied  roles w ith in  the C N S including the im m une response, m aintenance of 
hom eostasis, extracellular signalling, phagocytosis, antigen presentation and synaptic pruning [205] . 
In A D , m icroglia reaction w as initially  thou ght to be incidental and triggered by  A ß deposits and 
dystrophic neurites. M oreover, recent genom e-w ide association studies have established that the 
m ajority of AD risk loci are found in or near genes that are highly and som etim es uniquely expressed 
in m icroglia [206]. O n the other hand, a m ultitude of independent sources have suggested that 
neuroinflam m ation contributes to the pathogenesis of AD. Therefore, a hypothesis has been proposed 
that microglia could be critically involved in the early steps of AD and microglial targets are now being 
considered as the next im portant potential therapeutic targets.
Table 3. Emerging microglial targets in AD based on [205- 208].
Pathway Targets Evidence
Purinergic signalling
NOD-like receptor family 









-triggers TREM2 receptor 
expressed in myeloid cells 2
-TLR2
-TLR4





-P2 x 7R is up-regulated in AD 
-P2Y2R protective role 
-P2Y6R—small molecule from GliaCure 
claims to promote microglial phagocytosis 
through binding of the microglial 
purinergic P2Y6 receptor [209]
-P2Y12 plays an important role in 
homeostatic microglia
-NLRP3 inflammasome activation is a 
pathophysiological pathway in AD
-triggers the neuroinflammatory response 
-downstream TLR signalling through NFkB, 
activator protein 1 and IFN regulatory 
factor (IRF) pathways lead to 
proinflammatory gene transcription 
-CX3CL1 exerts an inhibitory signal, 
maintaining microglia in a resting state
-enzyme downstream of TNFa signalling, 
has been shown to mediate microglial 
responses in AD
It is also worth m entioning the innovative nanotechnology-based approaches in the treatm ent of 
AD, an approach that is seen as a great hope for developing new treatm ent strategies. The achievements 
of nanotechnology are particularly encouraging because they provide many benefits while overcoming 
the lim itations of conventional form ulations.
Recently, C hen et al. [210] reported the preparation of a m ethylene blue loaded m ultifunctional 
nanocom posite. The constructed nanocom posite has ultra-sm all ceria nanocrystals and iron oxide 
nanocrystals assem bled onto the surface of m esoporous silica nanoparticles, m ethylene blue loaded 
into its pores and, additionally, a tau  tracer, A m ino-T807, grafted onto the surface. The adopted 
strategy allow ed for the achievem ent of a prom ising synergistic effect as a result of RO S scavenging 
ability of ultra-sm all ceria nanocrystals, am eliorating m itochondrial oxidative stress-induced damage
and use of a tau aggregation inhibitor, m ethylene blue, w hich could be released in neurons to prevent 
hyperphosphorylated  tau aggregation. O n the other hand, G uo et al. [211] designed and optim ized 
a novel fusion peptide (TPL) com prising a BBB-penetrating peptide, TG N , and a neuron binding 
peptide, Tet1, through a four-glycine linker. Interestingly, TPL-modified nanoparticles led to an increase 
in BBB-penetration and neuron targeting efficacy, in com parison to the nanoparticles co-decorated 
w ith  the tw o m ono-ligands. M oreover, after the encapsulation of a neuroprotective peptide, NAP, 
the TPL nanoparticles reduced the intracellular RO S, show ed protection of m icrotubules against 
A ß25-35-induced toxicity, and rescued the O A-induced tau aggregation and neuronal apoptosis.
Another interesting study concerns the developm ent of a polymeric micelle drug delivery system 
consisting of the R A G E targeting peptide (Ab) derived from  A ß protein, an am phiphilic polym er 
w ith  R O S responsiveness and scavenging ability, and curcum in, a natural com pound w hich has 
been  described to target to A ß aggregation [212]. Such a type of nanosystem  has the ability to 
accum ulate in  the A D  brain  and initiate subsequent m icroglia-based m icroenvironm ent m odulation. 
M ore im portantly, it is possible that m ultiple targets w ithin  the A D  m icroenvironm ent could be 
controlled to reeducate the hyperactive m icroglia and protect dam aged neurons. The exam ples 
listed above confirm  the need for further intensive studies to obtain  better clin ical translation of 
m ultifunctional nanosized drug delivery system s.
6. C onclusions
The increasing num ber of potential biological targets for A D  raises the question of how  
to find m eaningful com binations o f targets for an  M TD Ls approach. A  pioneering study of a 
hum an pharm acology interaction netw ork revealed relationships betw een proteins in chem ical 
space and assessed the polypharm acology profile of ligands [213]. N ext, a com putational 
m odel to m ap the polypharm acology netw ork w as assem bled by  connecting targets according 
to the structural sim ilarity o f their binders (sim ilarity  ensem ble approach, SEA ) [214]. Thus far, 
the com putationally driven m ultitarget h it d iscovery has been successfully applied to the discovery 
of M TD Ls com bining galantam ine and m em antine [215] and triazinones as BA C E-1 and G SK -3ß 
inhibitors [216]. Besnard et al. outlined a strategy for the autom ated design of M TD Ls for the 
optim ization process of m ultitarget hits [217].
M odern drug discovery has the tools to screen m illions of com pounds or fragments to determine 
potential association w ith  AD. O set-G asque and M arco-Contelles have proposed that there is a need 
to find universal and polyvalent pharm acophoric groups able to m odulate diverse receptors or 
enzym atic system s [218]. For novel M TDL hits against AD, two applicable strategies have been used, 
nam ely, the fram ew ork com bination approach or fragm ent-based drug discovery (FBD D) [219- 221]. 
M eanwhile, Prati et al. proposed the adoption of both strategies, in parallel [222]. The identification of 
a high-quality starting hit is crucial for next steps towards lead optim ization. A high-quality starting 
h it is characterized by  a balanced m odulation of several targets, bu t it is still a challenge to choose 
the right com bination of targets. The m ain goal of M TD L design is to choose such com binations of 
targets that can provide a superior therapeutic effect and side-effect profile, com pared to the action 
of a selective ligand on its ow n. It requires a good understanding of target-disease associations, 
pathw ay-target-drug-disease relationships and adverse events profiling. H ow ever, the com plex 
interactions am ong potential A D  targets is com plicated  and the precise m echanism s are unclear. 
The application of a big-data research approach should be able to identify  the biological pathw ays 
and key m olecules involved in the aetiology of AD through the generation and analysis of large-scale 
transcriptome, epigenetic, proteome, and clinical data, thereby providing a rational and validated basis 
for extending the M TDL approach in AD [223].
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